Figure 2
Figure 2. Survival in patients less than 60 years of age by risk group and interval from diagnosis to treatment. (A) Survival by risk group. ------- indicates favorable (age ≤ 40 and de novo AML); - - - -, intermediate (age ≤ 40 and secondary AML, or age > 40 and de novo AML); and - · - · -, unfavorable (age > 40 and secondary AML). (B) Survival by treatment lag (favorable risk patients). (C) Survival by treatment lag (intermediate risk patients). (D) Survival by treatment lag (unfavorable risk patients). (B-D) ------- indicates less than or equal to 5-day treatment delay; and - - - -, more than 5-day treatment delay.

Survival in patients less than 60 years of age by risk group and interval from diagnosis to treatment. (A) Survival by risk group. ------- indicates favorable (age ≤ 40 and de novo AML); - - - -, intermediate (age ≤ 40 and secondary AML, or age > 40 and de novo AML); and - · - · -, unfavorable (age > 40 and secondary AML). (B) Survival by treatment lag (favorable risk patients). (C) Survival by treatment lag (intermediate risk patients). (D) Survival by treatment lag (unfavorable risk patients). (B-D) ------- indicates less than or equal to 5-day treatment delay; and - - - -, more than 5-day treatment delay.

Close Modal

or Create an Account

Close Modal
Close Modal